Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective

Feb

Today In Oncology

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective

A New Risk Model for Esophagectomy Draws on the STS National Database

Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA

Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors

ASCO and Conexiant Launch ASCO AI in Oncology

Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors